Analytical Data
-
Gene name
IRF4
- Application
-
Alternative Names
IRF4；MUM1；Interferon regulatory factor 4
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15306
-
Expression Region
1-451aa
-
AA Sequence
MNLEGGGRGGEFGMSAVSCGNGKLRQWLIDQIDSGKYPGLVWENEEKSIF RIPWKHAGKQDYNREEDAALFKAWALFKGKFREGIDKPDPPTWKTRLRCA LNKSNDFEELVERSQLDISDPYKVYRIVPEGAKKGAKQLTLEDPQMSMSH PYTMTTPYPSLPAQQVHNYMMPPLDRSWRDYVPDQPHPEIPYQCPMTFGP RGHHWQGPACENGCQVTGTFYACAPPESQAPGVPTEPSIRSAEALAFSDC RLHICLYYREILVKELTTSSPEGCRISHGHTYDASNLDQVLLPYPEDNGQ RKNIEKLLSHLERGVVPWMAPDGLYAKRLCQSRIYWDGPLALCNDRPNKL ERDQTCKLFDTQQFLSELQAFAHHGRSLPRFQVTLCFGEEFPDPQRQRKL ITAHVEPLLARQLYYFAQQNSGHFLRGYDLPEHISNPEDYHRSIRHSSIQ E
-
Molecular Weight
75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IRF4 (Interferon Regulatory Factor 4) is a critical transcription factor that plays a significant role in the immune system, particularly in the regulation of immune responses. It is primarily expressed in lymphocytes, including B cells and T cells, where it regulates the differentiation, proliferation, and function of these cells. Research has indicated that IRF4 is essential for the development of distinct immune lineages, such as plasma cells and follicular helper T cells, and it significantly influences the production of immunoglobulins. Given its pivotal role in adaptive immunity, IRF4 has also been implicated in various diseases, including autoimmune disorders and cancers, particularly lymphomas. The investigation of IRF4 recombinant protein serves multiple objectives, such as elucidating its structural properties, understanding its interaction with other proteins, and exploring its potential as a therapeutic target. By using recombinant technology, researchers can produce the IRF4 protein in a controlled environment, facilitating studies on its functional dynamics and involvement in immune regulation. Furthermore, as scientists seek to develop novel immunotherapies, characterizing the function of IRF4 through its recombinant form may reveal insights into its potential manipulation for clinical benefit. Thus, the study of IRF4 recombinant protein is instrumental in bridging fundamental immunological knowledge with therapeutic applications, aiming to harness the immune system for the treatment of various diseases.
